About this trial
The optimal surgical axillary staging technique in patients who convert from the clinically positive to clinically negative lymph node status under neoadjuvant therapy (cN+ → ycN0) remains to be clarified. Different strategies (axillary lymph node dissection, sentinel node biopsy, targeted axillary dissection) are currently used in different countries. A prospective analysis comparing these techniques regarding feasibility, safety, morbidity and surgical effort is urgently needed. Due to high complexity and discordant recommendations, a randomized trial comparing different techniques is hardly feasible. Therefore, the EUBREAST study group decided to initiate a prospective cohort study as an international project that aims at comparatively evaluating data on axillary staging after neoadjuvant therapy.
Eligibility criteria
Qualifiers
Signed informed consent form
Primary invasive breast cancer (confirmed by core biopsy)
cN+
cT1-4c
Disqualifiers
Distant metastasis
Recurrent breast cancer
Inflammatory breast cancer
Extramammary breast cancer
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
European Breast Cancer Research Association of Surgical Trialists
Lead sponsor
AWOgyn
Collaborator
AGO-B
Collaborator
North Eastern German Society of Gynaecological Oncology
Collaborator
GBG Forschungs GmbH
Collaborator
Claudia von Schilling Foundation for Breast Cancer Research
Collaborator
Ehmann-Stiftung Savognin
Collaborator